Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Down 7.1% in October

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 17,000 shares, a drop of 7.1% from the September 30th total of 18,300 shares. Based on an average daily trading volume, of 48,200 shares, the days-to-cover ratio is currently 0.4 days.

Hedge Funds Weigh In On Global X Genomics & Biotechnology ETF

Institutional investors and hedge funds have recently bought and sold shares of the stock. Insight Advisors LLC PA bought a new stake in Global X Genomics & Biotechnology ETF in the 1st quarter valued at $152,000. Centaurus Financial Inc. acquired a new stake in Global X Genomics & Biotechnology ETF during the second quarter worth about $146,000. James J. Burns & Company LLC bought a new position in Global X Genomics & Biotechnology ETF during the second quarter valued at about $181,000. Archford Capital Strategies LLC lifted its position in shares of Global X Genomics & Biotechnology ETF by 59.1% in the 2nd quarter. Archford Capital Strategies LLC now owns 36,871 shares of the company’s stock worth $385,000 after acquiring an additional 13,703 shares during the period. Finally, Sanctuary Advisors LLC acquired a new stake in shares of Global X Genomics & Biotechnology ETF during the 2nd quarter worth approximately $590,000. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Stock Down 1.9 %

NASDAQ GNOM traded down $0.20 during trading on Thursday, hitting $10.38. The company’s stock had a trading volume of 39,010 shares, compared to its average volume of 57,984. Global X Genomics & Biotechnology ETF has a 52 week low of $8.63 and a 52 week high of $12.53. The firm has a market cap of $75.88 million, a P/E ratio of -4.44 and a beta of 1.03. The firm has a 50 day moving average price of $11.04 and a 200 day moving average price of $10.81.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.